WO1997016967A1 - Compositions and methods for promoting blood component survival - Google Patents
Compositions and methods for promoting blood component survival Download PDFInfo
- Publication number
- WO1997016967A1 WO1997016967A1 PCT/US1996/017952 US9617952W WO9716967A1 WO 1997016967 A1 WO1997016967 A1 WO 1997016967A1 US 9617952 W US9617952 W US 9617952W WO 9716967 A1 WO9716967 A1 WO 9716967A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antioxidant
- blood
- population
- composition
- blood components
- Prior art date
Links
- 239000012503 blood component Substances 0.000 title claims abstract description 129
- 238000000034 method Methods 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 230000004083 survival effect Effects 0.000 title claims abstract description 14
- 230000001737 promoting effect Effects 0.000 title claims abstract description 6
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 176
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 96
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 66
- 230000006378 damage Effects 0.000 claims abstract description 40
- 230000036542 oxidative stress Effects 0.000 claims abstract description 35
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 25
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- -1 RBCs Substances 0.000 claims abstract description 9
- 238000000338 in vitro Methods 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 90
- 239000008280 blood Substances 0.000 claims description 62
- 210000004369 blood Anatomy 0.000 claims description 61
- 230000005855 radiation Effects 0.000 claims description 35
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical group OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 30
- 229960005155 tirilazad Drugs 0.000 claims description 27
- RBKASMJPSJDQKY-RBFSKHHSSA-N tirilazad Chemical compound O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 RBKASMJPSJDQKY-RBFSKHHSSA-N 0.000 claims description 26
- 238000003860 storage Methods 0.000 claims description 25
- 239000000126 substance Substances 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 19
- 229930003427 Vitamin E Natural products 0.000 claims description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 11
- 229940046009 vitamin E Drugs 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 10
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 150000002632 lipids Chemical group 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 102000016938 Catalase Human genes 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 7
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 7
- 230000006866 deterioration Effects 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 229960000984 tocofersolan Drugs 0.000 claims description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 210000001772 blood platelet Anatomy 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims description 4
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 210000003714 granulocyte Anatomy 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 108030002440 Catalase peroxidases Proteins 0.000 claims description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 3
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 3
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 239000002076 α-tocopherol Substances 0.000 claims description 3
- 235000004835 α-tocopherol Nutrition 0.000 claims description 3
- 230000005779 cell damage Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 230000035899 viability Effects 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 description 65
- 239000000523 sample Substances 0.000 description 42
- 108010061951 Methemoglobin Proteins 0.000 description 37
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 32
- 238000002474 experimental method Methods 0.000 description 29
- 238000011282 treatment Methods 0.000 description 29
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 27
- 239000003642 reactive oxygen metabolite Substances 0.000 description 20
- 230000003859 lipid peroxidation Effects 0.000 description 18
- 239000012528 membrane Substances 0.000 description 18
- 108010054147 Hemoglobins Proteins 0.000 description 17
- 102000001554 Hemoglobins Human genes 0.000 description 17
- 210000000601 blood cell Anatomy 0.000 description 15
- 230000003647 oxidation Effects 0.000 description 13
- 238000007254 oxidation reaction Methods 0.000 description 13
- 230000004792 oxidative damage Effects 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 11
- 210000003622 mature neutrocyte Anatomy 0.000 description 11
- 239000000306 component Substances 0.000 description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 9
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 9
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 9
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 108010053835 Catalase Proteins 0.000 description 5
- 208000021187 Transfusion associated graft versus host disease Diseases 0.000 description 5
- 230000036770 blood supply Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229940126707 lipid peroxidation inhibitor Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000007800 oxidant agent Substances 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 3
- 229940025294 hemin Drugs 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 2
- 239000012625 DNA intercalator Substances 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010019965 Spectrin Proteins 0.000 description 2
- 102000005890 Spectrin Human genes 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960001235 gentian violet Drugs 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000003206 sterilizing agent Substances 0.000 description 2
- 229940086735 succinate Drugs 0.000 description 2
- 150000003712 vitamin E derivatives Chemical class 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 description 1
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940116901 diethyldithiocarbamate Drugs 0.000 description 1
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010083487 hemichrome Proteins 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000906 photoactive agent Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 208000037629 renal transport of beta-amino acids Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000352 storage cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01009—Glutathione peroxidase (1.11.1.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Definitions
- Blood and blood cells contain natural antioxidant enzymes to protect against damage from reactive oxygen species (ROS).
- ROS reactive oxygen species
- the protective antioxidant effects diminish and blood cells and proteins are at increased risk for oxidative damage.
- additional oxidative damage may occur. Examples of such treatments include treatments designed to prevent transmission of microbial pathogens and treatments designed to prevent transfusion-associated graft- versus- host-disease (TA-GVHD).
- TA-GVHD is a devastating complication of blood transfusion.
- TA-GVHD results from engraftment and clonal expansion of allogeneic donor leukocytes.
- the present invention features compositions and methods for minimizing damage caused to blood components, such as RBCs, platelets, and granulocytes, by oxidative stress, e.g., the production of reactive oxygen species (ROS) and subsequent peroxidation ofthe membrane lipids and oxidation of membrane-bound proteins during or after gamma irradiation or initiated by a chemical or process described herein.
- ROS reactive oxygen species
- the invention is based, at least in part, on the discovery that antioxidants can significantly reduce oxidative stress- induced blood component damage.
- the present invention pertains to a composition which includes a population, e.g., an in vitro population, of blood components and an antioxidant.
- a population e.g., an in vitro population
- blood components which can be included in the compositions ofthe invention include cellular components, e.g., RBCs, granulocytes, lymphocytes, and platelets, and noncellular components, e.g., plasma proteins.
- oxidative stress e.g., induced by, for example, irradiation, e.g., gamma irradiation
- treatment with a chemical or process for the purpose of inactivating microbial agents e.g., a DNA intercalator, e.g., a photoactive agent which can be used as blood sterilizing agent, e.g., a psoralen, methylene blue, and gentian violet, a bleaching agent, an antimicrobial agent, or treatment with a chemical or process which minimizes or inhibits storage-related deterioration, damage and/or death of blood components
- these blood components can be mixed or contacted with an antioxidant.
- Antioxidants which can be included in these compositions include enzyme antioxidants such as superoxide dismutase (SOD), catalase, and glutathione peroxidase.
- enzyme antioxidants such as superoxide dismutase (SOD), catalase, and glutathione peroxidase.
- Other examples of antioxidants which can be used in the compositions ofthe present invention include water soluble antioxidants such as vitamin E analogs and vitamin C, lipid soluble antioxidants such as vitamin E (both natural and synthetic forms, d ⁇ -tocopherol, dl- ⁇ tocopherol, tocopheryl acetate, and succinate) and caretenoids, e.g., beta carotene.
- antioxidants which can be used in the compositions and methods ofthe invention include trace elements such as selenium (which is a cofactor for glutathione peroxidase), thiol compounds such as cysteine, e.g., N-acetyl cysteine, and reducing substances such as butylated hydroxytoluene (BHT).
- Preferred antioxidants for use in the present invention include jazaroids, e.g., tirilazad mesylate.
- the compositions ofthe invention include a pharmaceutically acceptable carrier or diluent.
- the composition is included within a container, e.g., a blood bag, for storage prior to use.
- the composition includes a population of RBCs, e.g., irradiated RBCs, and a lazaroid, e.g., tirilazad mesylate. Mixtures of antioxidants can also be included in the compositions ofthe invention.
- the present invention also pertains to methods for promoting or increasing survival of a population of blood components, e.g., RBCs, which has been subjected to oxidative stress, e.g., irradiation, treatment with a chemical or process for the purpose of inactivating microbial agents, or treatment with a chemical or process which minimizes or inhibits storage-related deterioration, damage, and/or death of blood components.
- oxidative stress e.g., irradiation
- treatment with a chemical or process for the purpose of inactivating microbial agents e.g., a chemical or process for the purpose of inactivating microbial agents
- treatment with a chemical or process which minimizes or inhibits storage-related deterioration, damage, and/or death of blood components e.g., as described above, the FDA recommended shelf-life of irradiated blood is 28 days from the day of irradiation.
- the shelf-life of irradiated blood which is treated according to the methods of this invention is increased to greater than 28 days, e.g., at least about 30 days, preferably at least about 35 days, still preferably at least about 40 days, and yet more preferably at least about 45 days, and most preferably at least about 50 days from the day of irradiation.
- These methods typically include contacting, in vitro, a population of oxidatively stressed blood components with an antioxidant in an amount and over a period of time effective to protect against oxidative stress-induced blood component damage or in an amount and over a period of time effective to increase the viability ofthe blood components, e.g., for a period of time greater than 28 days.
- a preferred antioxidant is a lazaroid, e.g., tirilazad mesylate.
- the invention provides rneffi ⁇ ds for increasing shelf-life of irradiated RBCs.
- These methods typically include contacting, in vitro, the irradiated RBCs with an antioxidant, e.g., a lazaroid, e.g., tirilazad mesylate, in an amount and over a period of time effective to protect against radiation-induced RBC damage.
- an antioxidant e.g., a lazaroid, e.g., tirilazad mesylate
- the present invention further pertains to methods for increasing survival of blood components in blood component transfusion recipient subjects.
- a population of blood components is subjected to oxidative stress, and then contacted with an antioxidant to form a transfusion mixture.
- the population of blood components can be contacted with an antioxidant prior to and/or during subjection to oxidative stress to form a transfusion mixture.
- the transfusion mixture is then administered to a recipient subject.
- the antioxidant is removed from the transfusion mixture prior to administration to the recipient subject.
- the antioxidant is included in the transfusion mixture upon administration to the transfusion recipient.
- Other aspects ofthe invention are methods for inhibiting oxidative stress-induced leukocyte-mediated damage to a population of blood components.
- Blood leukocytes and in particular, polymorphonuclear neutrophils (PMNs) are capable of generating ROS, e.g., superoxide anions, hydrogen peroxide, when activated, e.g., by exposure ofthe blood to oxidative stress induced by, for example, radiation, treatment with a chemical or process for the purpose of inactivating microbial agents, or treatment with a chemical or process which minimizes or inhibits storage-related deterioration, damage, and/or death of blood components.
- ROS damage other blood cells, e.g., RBCs, in the population of blood components.
- These methods include contacting a population of blood components, e.g., a blood sample, which includes leukocytes and at least one additional type of blood component, e.g., RBCs and/or platelets, with an antioxidant in an amount and over a period of time effective to protect against oxidative stress-induced leukocyte-mediated blood component damage or in an amount and over a period of time effective to increase the viability ofthe additional type of blood component, e.g., RBCs, e.g., for a period of time greater than 28 days.
- the antioxidant can be added to the population of blood components prior to, during and/or after the population of blood components is subject to oxidative stress.
- Figures 1A-1B are bar graphs showing the effects of increasing concentrations of t- butyl hydroperoxide (t-BHP) on the formation of thiobarbituric acid reactive substances (TBARS) ( Figure 1 A) and on the hemoglobin oxidation (measured by formation of methemoglobin) ( Figure IB) in RBC samples.
- t-BHP t-butyl hydroperoxide
- Figures 2A-2B are bar graphs showing the effects of gamma-irradiation on methemoglobin formation ( Figure 2 A) and on the TBARS formation ( Figure 2B) in RBC samples.
- Figures 3A-3B are bar graphs showing the effects ofthe combined treatment of gamma-irradiation and oxidant treatment on methemoglobin formation (Figure 3A) and on TBARS formation (Figure 3B) in RBC samples.
- Figure 4 is a bar graph showing the level of TBARS formation in RBC samples treated with t-BHP alone, BHT, a lipid peroxidation inhibitor, and t-BHP, dithiothreitol (DTT), another lipid peroxidation inhibitor, and t-BHP as well as TBARS formation in an untreated RBC sample.
- Figures 5A-5B are bar graphs showing the level of methemoglobin formation
- Figures 6A-6B are bar graphs showing the levels of methemoglobin foimation (Figure 6A) and TBARS formation (Figure 6B) in the RBC sample over the 4 week RBC storage period for RBC samples which were either exposed to gamma-irradiation and then stored in CPDA-1 at 4°C for 0-4 weeks or stored in CPDA-1 at 4°C for 0-4 weeks and then exposed to gamma irradiation.
- Figure 7 is a bar graph depicting the level of methemoglobin formation, over a six hour period, in RBCs treated with an inhibitor of SOD and then irradiated.
- Figure 8 is a bar graph depicting the level of methemoglobin formation, over a six hour period, in RBCs treated with an inhibitor of glutathione peroxidase and then irradiated.
- Figure 9 is a bar graph depicting the level of methemoglobin formation, over a six hour period, in RBCs treated with an inhibitor of catalase and then irradiated.
- Figure 10 is a bar graph depicting the level of methemoglobin formation in RBCs irradiated in the presence and absence of PMNs.
- Figures 11A-11B are bar graphs depicting the protective effect of vitamin E administration on radiation-induced methemoglobin formation (Figure 1 IA) and TBARS formation ( Figure 1 IB) in a blood sample.
- Figure 72 is a bar graph depicting the protective effect of tirilazad mesylate administration on radiation induced hemolysis of RBCs.
- Figure 13 is a bar graph depicting the protective effect of tirilazad mesylate administration on radiation induced lipid peroxidation in RBCs.
- compositions which include a population of blood components, e.g., a population of blood components in vitro, and an antioxidant or a mixture of two or more antioxidants.
- population refers to a group of two or more blood components, e.g., two or more blood cells, e.g., two or more RBCs.
- the blood components can be obtained from whole blood from a living organism, e.g., a mammal, e.g., a human, a rodent, a pig.
- the blood components ofthe compositions and methods ofthe invention can be cellular, e.g., RBCs (also referred to herein as erythrocytes), granulocytes, lymphocytes, and platelets and/or noncellular components, e.g., blood proteins.
- the blood components are RBCs.
- Antioxidants which can be used in the compositions and methods ofthe invention include compounds which can prevent, inhibit, minimize and/or at least partially ameliorate oxidative stress-induced blood component damage.
- the antioxidants prevent, inhibit, minimize and/or at least partially ameliorate detrimental effects of ROS on blood components, e.g., blood cells, e.g., RBCs.
- inhibitors of lipid peroxidation are useful as antioxidants.
- Antioxidants which can be included in these compositions include enzyme antioxidants such as SOD, polyethylene glycol-SOD, catalase, and glutathione, e.g., glutathione peroxidase.
- enzyme antioxidants such as SOD, polyethylene glycol-SOD, catalase, and glutathione, e.g., glutathione peroxidase.
- Other examples of antioxidants which can be used in the compositions ofthe present invention include water soluble antioxidants such as vitamin E analogs and vitamin C, lipid soluble antioxidants such as vitamin E (both natural and synthetic forms, d ⁇ -tocopherol, dl- ⁇ tocopherol, tocopheryl acetate, and succinate) and caretenoids, e.g., beta carotene.
- Preferred antioxidants for use in the present invention include lazaroids, e.g., tirilazad mesylate.
- Lazaroids are a class of 21 -aminosteroids which inhibit membrane lipid peroxidation and also act as free radical scavengers.
- Preferred lazaroids include tirilazad and its mesylate salt, tirilazad mesylate (which is commercially available from Upjohn), 5 ⁇ -tirilazad, 5 ⁇ -tirilazad, 6 ⁇ - hydroxytirilazad, 6 ⁇ - hydroxytirilazad, and the salts thereof, e.g., the pharmaceutically acceptable salts thereof.
- tirilazad and its mesylate salt which is commercially available from Upjohn
- 5 ⁇ -tirilazad 5 ⁇ -tirilazad
- 6 ⁇ - hydroxytirilazad 6 ⁇ - hydroxytirilazad
- the salts thereof e.g., the pharmaceutically acceptable salts thereof.
- Examples of dosages or amounts of antioxidants which are included in the compositions ofthe invention are as follows: 1) vitamin E is included in the compositions ofthe invention in concentrations which range from about 10 mg to about 500 mg, preferably about 250 mg/unit of whole blood (i.e., about 250 mg/400ml of whole blood or packed red blood cells); 2) vitamin C is included in the compositions ofthe invention in concentrations which range from about 5 mg to about 50 mg per 100 ml of whole blood or packed red blood cells; 3) beta-carotene is included in the compositions ofthe invention in concentrations which range from about 5 mg to about 50 mg/400 ml of whole blood or packed red blood cells; and 4) tirilazad mesylate is included in the compositions ofthe invention in concentrations which range from about 0.01 mg/ml to about 0.2 mg/ml of whole blood or packed red blood cells.
- the compositions also include a pharmaceutically acceptable carrier or diluent.
- Pharmaceutically acceptable carriers and diluents include sterile saline and aqueous buffer solutions. The use of such carriers and diluents is well known in the art. The solutions are sterile and stable under the conditions of manufacture and storage.
- Pharmaceutically acceptable carriers or diluents suitable for use in the compositions ofthe present invention include standard media used to store and administer blood to human recipients. These media are known in the art and include citrate, phosphate, dextrose, adenine-formula 1 (CPDA-1) and bicarbonate buffers. For other examples of such media see Jeter, E.K et al. (1991) -4w?. Clin. Lab. Sci. 21(3):177-186.
- the compositions ofthe invention can be included in a container, e.g., a container suitable for storing the compositions ofthe invention, e.g., a blood bag.
- the blood components ofthe compositions ofthe invention are oxidatively stressed.
- the language "oxidatively stressed” refers to blood components which have been subjected to a treatment which results in oxidative stress of the blood components. Oxidative stress includes detrimental effects on the blood components which are caused by ROS and subsequent peroxidation ofthe membrane lipids and oxidation of membrane-bound proteins.
- Oxidative stress includes detrimental effects on the blood components which are caused by ROS and subsequent peroxidation ofthe membrane lipids and oxidation of membrane-bound proteins.
- Various factors can initiate the production of ROS. For example, exposure of a population of blood components to selected agents which confer a desired property on the blood components, e.g., irradiation, e.g., gamma irradiation which renders lymphocyte blood components nonreproductive, can initiate the production of ROS.
- the blood components can also be treated with chemicals or processes which minimize or inhibit storage-related deterioration (or decrease in viability, and/or damage) of blood components. Treatment ofthe blood components with such chemicals and processes can result in production of ROS and/or other agents which cause damage to the blood components and decrease their viability.
- the present invention also pertains to methods for promoting or increasing the survival, e.g., survival in vitro, of a population of blood components, e.g., a population of RBCs, which has been subjected to oxidative stress.
- the shelf-life of oxidatively stressed blood components which are treated according to the methods of this invention is increased to at least about 30 days, preferably at least about 35 days, still preferably at least about 40 days, and yet more preferably at least about 45 days to about 48 days, and most preferably at least about 50 days or more from the day of initiation of oxidative stress.
- These methods include contacting, in vitro, a population of oxidatively stressed blood components with an antioxidant in an amount and over a period of time effective to protect against, e.g., inhibit or minimize, oxidative stress-induced blood component damage or in an amount and over a period of time effective to increase the viability ofthe blood components, e.g., for a period of time greater than 28 days, the FDA recommended shelf-life of oxidatively stressed, e.g., irradiated, blood.
- the blood components are contacted with the antioxidant prior to subjection to the oxidative stress, e.g., radiation, e.g., treatment with a chemical or process for the purpose of inactivating microbial agents, treatment with a chemical or process which minimizes or inhibits storage-related deterioration and damage of blood components.
- the blood components e.g., RBCs
- the detrimental effects of oxidative stress on blood components can be decreased, inhibited, or minimized if the blood components are contacted or incubated with an antioxidant for as little as a few minutes, e.g., at least about 30 minutes, and at dosages and in amounts described herein.
- the blood components are contacted with the antioxidant, or a combination of antioxidants, for a period of time greater than a few minutes, e.g., 30 minutes or more.
- blood components can be incubated with antioxidants for extended periods of time, e.g., hours and days, without causing detrimental effects on the blood cells or other side effects.
- the antioxidants which can be used as described herein can be administered to a human recipient together with the blood components. Examples of antioxidants which can be used in the methods ofthe invention are described herein.
- the present invention further pertains to methods for increasing survival of blood components, e.g., RBCs, in blood component transfusion recipient subjects. These methods include contacting a population of blood components with at least one antioxidant to form a transfusion mixture, subjecting the transfusion mixture to oxidative stress and administering the oxidatively stressed transfusion mixture to a recipient subject.
- the population of blood components is subjected to oxidative stress prior to the addition ofthe antioxidant.
- the antioxidant is removed from the transfusion mixture prior to the administering step.
- the blood components e.g., RBCs
- the blood components are contacted with the antioxidant or a combination of antioxidants in an amount and over a period of time effective to protect against oxidative stress or in an amount and over a period of time effective to increase the viability of blood components e.g., RBCs, e.g., for a period of time greater than 28 days.
- the phrase "transfusion mixture” refers to a population of blood components which includes an antioxidant or which has been contacted with an antioxidant.
- the blood components are RBCs which are exposed to oxidative stress in the form of irradiation, e.g., gamma irradiation.
- a blood cell e.g., RBC
- Blood cells, e.g., RBCs, treated according to the present invention and then irradiated and transfused into a recipient subject exhibit a viability of greater than 70% after 24 hours.
- the viability ofthe blood cells, e.g., RBCs, treated according to the methods ofthe present invention, 24 hours after transfusion is about 75%, more preferably about 80%, and most preferably about 90% or greater.
- the transfusion mixture is typically administered in a formulation which is compatible with the route of administration.
- An example of a suitable route of administration is intravenous injection (either as a single infusion or multiple infusions).
- the terms "subject” or "recipient subject” are used interchangeably herein and refer to mammals, particularly humans, who are to receive the compositions ofthe present invention.
- the antioxidant can be administered in vivo to a subject and the blood components removed from the subject and oxidatively stressed, e.g., irradiated.
- blood components for use in the compositions and methods ofthe invention can be obtained from the blood of a human patient, e.g., an autologous donor, who has previously been administered an antioxidant for at least about one to two weeks or more.
- Still other aspects ofthe invention are methods for inhibiting white blood cell
- leukocyte mediated oxidative stress-induced damage to a population of blood components.
- Blood leukocytes and in particular, polymo ⁇ honuclear neutrophils (PMNs) are capable of generating ROS, e.g., superoxide anions, hydrogen peroxide, when activated, e.g., by exposure ofthe blood to radiation or other chemicals or processes described herein.
- ROS damage other blood components, e.g., blood cells, e.g., RBCs, in the population of blood components.
- These methods include contacting a population of blood components which includes leukocytes and at least one additional type of blood component with an antioxidant in an amount and over a period of time effective to protect against oxidative stress-induced leukocyte-mediated blood component damage or in an amount and over a period of time effective to increase the viability of blood components, e.g., RBCs, e.g., for a period of time greater than 28 days.
- the antioxidant can be added to the population of blood components prior to, during, and/or after the population of blood components is subject to oxidative stress.
- the antioxidant or a combination of antioxidants is added to the population of blood components prior to subjection to oxidative stress.
- Lipid peroxidation can damage RBC membrane structure with formation of membrane pores through which intracellular components, including hemoglobin and potassium ion, can leak. This increased pore formation results in leakage of potassium ion and altered water permeability and, eventually, in cell lysis. Lipid peroxidation also causes polymerization of membrane components and decreases cell deformability. Moreover, peroxidant injury, initiated in phospholipid and other lipid components ofthe membrane can be transmitted to neighboring substances such as membrane proteins. Spectrin, a major protein component ofthe RBC membrane skeleton, can be cross-linked in this manner, resulting in decreased RBC deformability.
- Malonyldialdehyde a secondary product of lipid peroxidation, is capable of cross-linking membrane components containing amino groups. MDA can increase membrane rigidity and decrease RBC deformability.
- the detection of MDA using its reaction with thiobarbituric acid is an indicator of lipid peroxidation.
- the product of this reaction thiobarbituric acid reactive substances (TBARS) is a chromophore with a maximum abso ⁇ tion at 532 nm. Details ofthe TBARS assay for measuring oxidative damage to lipid membranes used herein can be found in Slater, T.F. et al. (1984) Meth. Enzymol. 105:283-293, the contents of which are hereby inco ⁇ orated by reference.
- Hemoglobin can react with ROS to form methemoglobin which may form other oxidized products of hemoglobin. These products, which can be unstable and which may ultimately bind to the RBC membrane, include single chain hemoglobin, hemin, and hemichrome. Hemin has been shown to extensively bind to spectrin, to foster oxidative damage, and to mediate a direct detergent-like effect on the RBC membrane, potentially leading to disruption and lysis. Hemichromes induce topographical changes in the membrane surface and generate free hemin which affects the membrane further.
- t-BHP t-butyl hydroperoxide
- Figure 1 A is a bar graph showing the effects of increasing concentrations of t-BHP on the formation of TBARS in RBCs. As demonstrated by this Figure, lipid peroxidation in RBCs increases with increasing doses ofthe oxidant t-BHP.
- Figure IB is a bar graph showing the effects of increasing concentrations of t-BHP on methemoglobin formation. As shown in this Figure, methemoglobin formation and thus, hemoglobin oxidation, increases with increasing doses of t-BHP.
- Figure 2A is a bar graph showing the effects of increasing doses of gamma- irradiation on the methemoglobin formation.
- Figure 2 A demonstrates that the methemoglobin formation increases with increasing doses of gamma-irradiation. Methemoglobin formation is translated into percent hemoglobin oxidation according to the method described in Winterbourn, CC. "Reaction of Superoxide with Hemoglobin" in CRC Handbook of Methods for Oxygen Radical Research. Greenwald, R.A. ed. (CRC Press, Boca Raton, 1985) pp. 137-141, the contents of which are hereby inco ⁇ orated by reference.
- FIG. 2B is a bar graph showing the effect of gamma- irradiation on the level of TBARS formation in an RBC sample which was not irradiated and an RBC sample which was irradiated. As demonstrated by this Figure, the level of TBARS formation in the irradiated RBC sample was significantly greater than that in the non-irradiated RBC sample.
- EXAMPLE III EFFECTS OF COMBINED TREATMENT WITH GAMMA-
- the first experiment two groups of RBC samples were used.
- the first group which was not irradiated, was treated with increasing concentrations of t-BHP (0, 500, 750, and 1000 ⁇ M) and the second group was first exposed to 50 Gy of gamma-irradiation.
- d e second group was treated with increasing concentrations of t-BHP.
- the extent of oxidative damage in each group was then assessed by measuring methemoglobin formation in the RBCs. The results of this experiment are shown in Figure 3 A.
- Figure 3 A is a bar graph showing the effect of gamma-irradiation and t-BHP treatment on the level of methemoglobin formation in an RBC sample over various doses of t-BHP.
- Figure 3 A demonstrates that radiation treatment combined with t-BHP treatment resulted in increased methemoglobin formation as compared to treatment with t-BHP alone. This increase was observed over a range of increasing t-BHP concentrations.
- two groups of RBC samples were also used. The first group, which was not irradiated, was treated with 1500 ⁇ M t-BHP and the second group was first treated with t-BHP and then exposed to 50 Gy of gamma-irradiation.
- Figure 3B is a bar graph showing the effect of gamma-irradiation and t-BHP treatment on the level of TBARS formation in an RBC sample.
- Figure 3B demonstrates that radiation treatment combined with t-BHP treatment resulted in increased TBARS formation compared to the sample treated with t-BHP alone.
- FIG. 5 A depicts a bar graph showing the levels of methemoglobin formation in the RBC sample over the 4 week RBC storage period. As shown in this Figure, methemoglobin formation increased as the storage period ofthe RBC samples increased.
- an RBC sample was stored in CPDA-1 at 4°C for 0-4 weeks. Each week, an aliquot ofthe RBC sample was taken and the formation of TBARS in the aliquot was measured.
- Figure 5B depicts a bar graph showing the levels of TBARS formation in the RBC sample over the 4 week RBC storage period. As shown in this Figure, TBARS formation increased as the storage period ofthe RBC samples increased.
- Figure 6 A depicts a bar graph showing the levels of methemoglobin formation in the RBC sample over the 4 week RBC storage period for RBC samples which were either irradiated and then stored at 4°C for 0-4 weeks or stored at 4°C for 0-4 weeks and then irradiated.
- methemoglobin formation increased as the storage period ofthe RBC samples increased in both the samples which were irradiated first and the samples which were first stored and then irradiated.
- FIG. 6B depicts a bar graph showing the levels of TBARS formation in the RBC sample over the 4 week RBC storage period for RBC samples which were either irradiated and then stored at 4°C for 0-4 weeks or stored at 4°C for 0-4 weeks and then irradiated.
- TBARS formation increased in both the samples which were irradiated first and the samples which were first stored and then irradiated.
- EXAMPLE VH EFFECTS OF INHIBITION OF RED BLOOD CELL ANTIOXIDANT ENZYMES ON RED BLOOD CELLS
- RBC antioxidant enzymes such as SOD, catalase, and glutathione peroxidase (GSH-PX)
- SOD sulfur dioxide
- catalase glutathione peroxidase
- GSH-PX glutathione peroxidase
- RBC SOD activity was inhibited by incubation of RBCs at 10% hematocrit for 2 hours at 37°C with 50 mM diethyldithiocarbamate in HBSS. Heikkila, R.E. et al. (1976) J. Biol. Chem. 251 :2182-2185.
- RBC GSH was depleted by incubation ofthe cells in 10% hematocrit for 60 minutes with 2 mM 1 -chloro-2,4-dinitrobenzene in HBSS. Awathi, Y.C. et al. (1981) Blood 58:733-738.
- the cells were washed twice following exposure to these inhibitors. After these washes, the cells were exposed to 50 Gy of gamma irradiation. The formation of methemoglobin was measured 2, 4, and 6 hours after irradiation.
- Figure 7 is a bar graph depicting the level of methemoglobin formation, over a six hour period, in RBCs treated with an inhibitor of SOD and then irradiated. As demonstrated by this Figure, inhibition of SOD resulted in significant hemoglobin oxidation.
- Figure 8 is a bar graph depicting the level of methemoglobin formation, over a six hour period, in RBCs treated with an inhibitor of GSH. As demonstrated in this Figure, inhibition of GSH also resulted in significant hemoglobin oxidation.
- Figure 9 is a bar graph depicting the level of methemoglobin formation, over a six hour period, in RBCs treated with an inhibitor of catalase.
- leukocytes white blood cells
- PMNs polymo ⁇ honuclear neutrophils
- Figure 10 is a bar graph depicting the level of methemoglobin formation in irradiated RBCs in the presence and absence of PMNs. As demonstrated in this Figure, the extent of radiation-induced hemoglobin oxidation was much greater in the presence of leukocytes than in the absence of leukocytes. These data indicate that PMNs are responsible for the enhancement of radiation-induced damage of RBCs. Further experiments have demonstrated that irradiation of PMNs results in formation of superoxide anion, which is a ROS.
- vitamin E dl-alpha tocopherol
- lipid peroxidation inhibitor a powerful antioxidant and lipid peroxidation inhibitor
- Figure 1 1 A is a bar graph showing the effect of vitamin E administration on radiation-induced methemoglobin formation in the blood sample.
- Vitamin E treatment reduced radiation-induced hemoglobin oxidation by about 50%.
- Figure 1 IB is a bar graph showing the effect of vitamin E administration on radiation-induced TBARS formation in the blood sample.
- vitamin E treatment significantly reduced radiation-induced TBARS formation (lipid peroxidation) in the blood sample.
- the blood bag was centrifuged at 4°C for 8 minutes at 4000 RPM. Then the plasma was transferred to the attached satellite bag and discarded.
- the packed RBC was washed with PBS in three steps. In each step, the RBC suspension was centrifuged (at 3000, 4000, 5000 RPM) for 3 minutes at 4°C and each time the supernatant was discarded. The washed RBC was then divided into four equal aliquots.
- Tirilazad mesylate was added to two ofthe aliquots, #2 and #4, (Table 1) with a final concentration of 0.05 mg/ml RBC. All four aliquots were incubated at 37°C for 20 minutes. Following the incubation the aliquots #3 and #4 were irradiated with 50 Gy gamma-irradiation (Table 1).
- FIG. 12 is a bar graph depicting the protective effect of tirilazad mesylate administration on radiation induced hemolysis of RBCs. Table 2 and Figure 12 demonstrate that the addition of tirilazad mesylate improved radiation induced hemolysis. Moreover, tirilazad mesylate not only improved radiation damage, but also improved the overall viability ofthe cells following storage. - 17 -
- FIG. 13 is a bar graph depicting the protective effect of tirilazad mesylate administration on radiation induced lipid peroxidation in RBCs.
- the results depicted in Table 3 and Figure 13 demonstrate that the addition of tirilazad mesylate protected the intact RBC against lipid peroxidation and irradiation.
- the effect of tirilazad mesylate is more pronounced in stored irradiated and non-irradiated cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2237180 CA2237180A1 (en) | 1995-11-09 | 1996-11-08 | Compositions and methods for promoting blood component survival |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US642295P | 1995-11-09 | 1995-11-09 | |
US60/006,422 | 1995-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997016967A1 true WO1997016967A1 (en) | 1997-05-15 |
Family
ID=21720804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/017952 WO1997016967A1 (en) | 1995-11-09 | 1996-11-08 | Compositions and methods for promoting blood component survival |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1997016967A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998046073A1 (en) * | 1997-04-16 | 1998-10-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Improved storage and maintenance of blood products |
WO2000074483A1 (en) * | 1999-06-08 | 2000-12-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Improved storage and maintenance of blood products including red blood cells and platelets |
EP2540306A1 (en) * | 2010-02-23 | 2013-01-02 | Terumo Kabushiki Kaisha | Additive for erythrocyte-rich solution, and container for medical purposes |
US8871434B2 (en) | 2008-03-21 | 2014-10-28 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
US8968992B2 (en) | 2008-03-21 | 2015-03-03 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
WO2015113988A1 (en) * | 2014-01-30 | 2015-08-06 | F. Hoffmann-La Roche Ag | Stabilization of whole blood at room temperature |
US9409128B2 (en) | 2009-10-23 | 2016-08-09 | Fenwal, Inc. | Methods for storing red blood cell products |
DE102017218847A1 (en) | 2017-10-23 | 2019-04-25 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for improving the stability of blood and blood products |
US10591472B2 (en) | 2012-08-13 | 2020-03-17 | Minicare B.V. | Use of antioxidants in methods and means for detection of target molecules in a blood sample |
CN114246846A (en) * | 2021-12-03 | 2022-03-29 | 宫念樵 | Application of methyl eugenol in prolonging service life of red blood cells |
CN115590014A (en) * | 2022-09-23 | 2023-01-13 | 无锡托马自然生物技术有限公司(Cn) | Erythrocyte preservation solution and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232844A (en) * | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
-
1996
- 1996-11-08 WO PCT/US1996/017952 patent/WO1997016967A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232844A (en) * | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
Non-Patent Citations (5)
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998046073A1 (en) * | 1997-04-16 | 1998-10-22 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Improved storage and maintenance of blood products |
WO2000074483A1 (en) * | 1999-06-08 | 2000-12-14 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Improved storage and maintenance of blood products including red blood cells and platelets |
US8871434B2 (en) | 2008-03-21 | 2014-10-28 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
US8968992B2 (en) | 2008-03-21 | 2015-03-03 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
US9409128B2 (en) | 2009-10-23 | 2016-08-09 | Fenwal, Inc. | Methods for storing red blood cell products |
US9943077B2 (en) | 2009-10-23 | 2018-04-17 | Fenwal, Inc. | Methods for storing red blood cell products |
US11864553B2 (en) | 2009-10-23 | 2024-01-09 | Fenwal, Inc. | Methods and systems for providing red blood cell products with reduced plasma |
US8889237B2 (en) | 2010-02-23 | 2014-11-18 | Terumo Kabushiki Kaisha | Excipient system and medical container for erythrocyte enriched liquid |
EP2540306A4 (en) * | 2010-02-23 | 2013-08-21 | Terumo Corp | Additive for erythrocyte-rich solution, and container for medical purposes |
EP2540306A1 (en) * | 2010-02-23 | 2013-01-02 | Terumo Kabushiki Kaisha | Additive for erythrocyte-rich solution, and container for medical purposes |
US10591472B2 (en) | 2012-08-13 | 2020-03-17 | Minicare B.V. | Use of antioxidants in methods and means for detection of target molecules in a blood sample |
WO2015113988A1 (en) * | 2014-01-30 | 2015-08-06 | F. Hoffmann-La Roche Ag | Stabilization of whole blood at room temperature |
CN105939601A (en) * | 2014-01-30 | 2016-09-14 | 豪夫迈·罗氏有限公司 | Stabilization of whole blood at room temperature |
CN105939601B (en) * | 2014-01-30 | 2020-03-10 | 豪夫迈·罗氏有限公司 | Stabilization of whole blood at room temperature |
DE102017218847A1 (en) | 2017-10-23 | 2019-04-25 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for improving the stability of blood and blood products |
CN114246846A (en) * | 2021-12-03 | 2022-03-29 | 宫念樵 | Application of methyl eugenol in prolonging service life of red blood cells |
CN115590014A (en) * | 2022-09-23 | 2023-01-13 | 无锡托马自然生物技术有限公司(Cn) | Erythrocyte preservation solution and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Weiss et al. | Monocyte and granulocyte-mediated tumor cell destruction. A role for the hydrogen peroxide-myeloperoxidase-chloride system. | |
US5709992A (en) | Method for disinfecting red blood cells | |
Weiss et al. | Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. | |
US5281392A (en) | Method for disinfecting red blood cells, blood products, and corneas | |
KR102701687B1 (en) | Anaerobic blood storage and pathogen inactivation methods | |
Anand et al. | Radiation‐induced red cell damage: role of reactive oxygen species | |
EP1345491B1 (en) | Storage solution containing photosensitizer for inactivation of biological contaminants | |
Yamaguchi et al. | Role of intracellular SOD in protecting human leukemic and cancer cells against superoxide and radiation | |
CZ298671B6 (en) | Method for improving protection of membrane against decomposition and suppression of concentrated thrombocyte hemolysis during their storage within a container, method of consistent sterilization thereof, leukocyte suppression treatment process and c | |
EP0544895A1 (en) | Method for inactivating pathogens in a body fluid. | |
WO1997016967A1 (en) | Compositions and methods for promoting blood component survival | |
US20030228564A1 (en) | Nitric oxide in a pathogen inactivation process | |
CZ20014078A3 (en) | Method for storing and maintaining blood products including erythrocytes and blood platelets | |
US5912241A (en) | Methods of use of phthalocyanines to inactivate blood borne parasites | |
Katz et al. | Effect of radiation on red cell membrane and intracellular oxidative defense systems | |
US7220747B2 (en) | Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer | |
WO2003066109A1 (en) | Nitric oxide in a pathogen inactivation process | |
JP2004520448A (en) | Virus inactivation method using antioxidants | |
CA2485663C (en) | Method for extended storage of blood and blood components | |
WO1998015297A1 (en) | Method for the sterilization of biological materials | |
Robertson et al. | The use of diphenylene iodonium, an inhibitor of NADPH oxidase, to investigate the antimicrobial action of human monocyte derived macrophages | |
Lemoli et al. | Dye-mediated photolysis is capable of eliminating drug-resistant (MDR+) tumor cells | |
Linas et al. | Endothelial cells protect vascular smooth muscle cells from H2O2 attack | |
CA2237180A1 (en) | Compositions and methods for promoting blood component survival | |
WO1991016911A1 (en) | Decontamination of whole blood and cellular components by phenthiazin-5-ium-dyes plus light |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2237180 Country of ref document: CA Ref country code: CA Ref document number: 2237180 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996940769 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996940769 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97518350 Format of ref document f/p: F |
|
122 | Ep: pct application non-entry in european phase |